Click a topic below for an index of articles:

 

New Material

Home

Donate

Alternative Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Projects

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper
info@heart-intl.net

 

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”


F.D.A. Panel Recommends Approval of Hepatitis B Drug

http://query.nytimes.com/gst/abstract.html?res=F70617FE355F0C748CDDA10894DA404482
Business/Financial Desk | August 7, 2002, Wednesday
 

By ANDREW POLLACK (NYT) 579 words
Late Edition - Final , Section C , Page 3 , Column 1

ABSTRACT - FDA advisory committee unanimously recommends approval for Gilead Sciences drug adefovir for hepatitis B (S) A Food and Drug Administration advisory committee unanimously recommended approval yesterday for the Gilead Sciences drug adefovir for hepatitis B, a viral infection for which there are few good treatments.

  



If the F.D.A. follows the panel's recommendation, as it usually does, the once-a-day pill could be on the market by September, said John Milligan, senior vice president at Gilead, a biotechnology company in Foster City, Calif.